Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (20638)	5/13/1998 5:10:00 PM
From: Henry Niman	Respond to of 32384

Speaking of FDA related matters, I think that Ergoset comes up for review tomorrow. ERGO's recent price movement doesn't show much confidence by shareholders. I think that an FDA rejection would be a modest plus for LGND. JNJ would know that they bet on the wrong horse AGAIN and that might get them talking to AGN AGAIN!

To: John O'Neill who wrote (20638)	5/14/1998 10:08:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

JO, I just checked out the FDA site and it looks like ERGO will be presenting today: ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE DATE AND TIME: May 13, 14, and 15, 8 a.m. LOCATION: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD. CONTACT: Kathleen R. Reedy or LaNise S. Giles, Center for Drug Evaluation and Research, 301-443-5455. On May 14, the committee will discuss Ergoset, (bromocryptine mesylate, Ergoscience) as monotherapy as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus, whose hyperglycemia cannot be satisfactorily managed with diet alone; or concomitantly with a sulfonylurea when diet and Ergoset alone do not result in glycemic control.